Table 3.
Frequency distribution of native kidney disease in large European kidney biopsy registries
| Author | Region Population | Timeframe Biopsies (N) | Age (years) M/F (%) | Freq. | IgAN (%) | FSGS (%) | MCD (%) | MN (%) | MPGN (%) | LN (%) | AAV (%) | AMY (%) | DKD (%) | TIN (%) | NScl (%) | Dx | Comments |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Rivera et al. [13] 2002 | SpainNational40 million | 1994–19996525 biopsies (A)491 biopsies (P) | NA60/40 (A) | A | 14.6 | 9.7 | 6.6 | 10.3 | 4.5 | 8.8 | 7.8 | 4.3 | 1.0 | NA | 5.9 | Pr. | Spanish Renal Registry, 70.4% participation of centres in Spain |
| López-Gómez et al. [10] 2020 | SpainNational40 million | 1994–201925 440 biopsies (A)1231 biopsies (P) | 50 (A + P)60/40 (A) | A + P | 14.6 | 8.0 | 6.8 | 9.9 | 3.9 | 8.7 | 6.8 | 3.8 | 4.8 | NA | 5.3 | Pr. | Spanish Renal Registry |
| Schena et al. [20] 1997 | ItalyNational56.8 milliona | 1987–199313 835 biopsies (A + P) | NA65/35 (A + P) | A + P | 21.1 | 7.1 | 4.7 | 12.4 | 4.0 | 6.7 | 3.4 | 2.7 | NA | 4.0 | NA | ERA-EDTA PRD | Italian Registry of Renal Biopsies, 96% participation of centres in Italy |
| Gesualdo et al. [22] 2004 | ItalyNational56.9 millionb | 1996–200013 132 biopsies (A + P) | NANA | A + P | NA | NA | NA | NA | NA | NA | NA | NA | NA | ∼5.3 | NA | ERA-EDTA PRD | Italian Registry of Renal Biopsies |
| Zaza et al. [6] 2013 | ItalyRegionalc5 million | 1998–20104378 biopsies (A) | 50.4 (A)62/38 (A) | A | NA | NA | NA | NA | NA | NA | NA | NA | NA | ∼5.5 | NA | Pr. | ‘Triveneto’ Register of Renal Biopsies |
| Maixnerova et al. [7] 2015 | Czech RepublicNational10.3 million | 1994–20119051 biopsies (A)1421 biopsies (P) | 44.5 (A)58/42 (A) | A + P | 20.5 | 6.9 | 6.1 | 7.1 | 3.2 | 7.1 | 5.7 | 3.1 | 4.1 | 3.3 | 3.0 | Pr. | Czech Registry of Renal Biopsies |
| Perkowska-Ptasinska et al. [14] 2017 | PolandNational38.5 million | 2009–20147349 biopsies (A)2939 biopsies (P) | NA54/46 (A) | A | 20.0 | 15.0 | 5.5 | 11.2 | 4.6 | 8.4 | 5.5 | 4.5 | 3.7 | 1.9 | 0.7 | Pr. | Polish Registry of Renal Biopsies |
| Brazdziute et al. [12] 2015 | LithuaniaNational3.4 milliond | 1994–20123213 biopsies (A)427 biopsies (P) | 43.2 (A + P)58/42 (A + P) | A + P | 20.2 | 7.8 | 4.9 | 4.7 | 7.4 | 2.3 | NA | 6.6 | 1.2 | 6.1 | 2.7 | Pr. | No formal registry, 11 centres |
| McQuarrie et al. [8] 2009 | UKRegionale4.2 million | 2002–20062480 biopsies (A) | 55.6 (A)57/43 (A) | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | NA | ERA-EDTA PRD | Scottish Renal Biopsy Registry |
| Wirta et al. [11] 2008 | FinlandRegionalf0.4 millionf0.8 millionf | 1980–20003310 biopsies (A + P) | 38–52g (A + P)59/41 (A + P) | A + P | 21.7 | 2.4 | 3.1 | 7.3 | 2.4 | NA | NA | NA | NA | 9.0h14.7h | NA | SNOMED | No formal registry, 6 centres |
| Covic et al. [15] 2006 | RomaniaRegionali6.2 million | 1995–2004606 biopsies (A) | 38.5 (A)52/48 (A) | A | 19.1 | 7.6 | 5.6 | 7.4 | 19.5 | 7.8 | 5.4 | 3.1 | NA | 1.5 | NA | Pr. | Two referral centres, >50% of all biopsies performed in Romania |
| Naumovic et al. [17] 2009 | Serbia1 centrej7.5 million | 1987–20061626 biopsies (A) | 39.1 (A)51/49 (A) | A | 7.7 | 12.1 | 4.8 | 12.6 | 6.7 | 10.1 | 2.3 | 1.4 | NA | 2.7 | 3.6 | Pr. | Single nephrology centre in Serbia |
| Brkovic et al. [16] 2018 | Serbia1 centrek7.2 million | 2007–2014665 biopsies (A) | 42 (A)50/50 (A) | A | 9.0 | 12.5 | 3.8 | 17.3 | 4.8 | 17.7 | 4.4 | 0.9% | NA | ∼2.1 | NA | Pr. | Single nephrology centre in Serbia |
| O'Shaughnessy et al. [24] 2018 | EuropeInternationalNA | 2006–2018l19 302 biopsies (A + P)m | 48 (A + P)56/44 (A + P) | A + P | 16.2 | 11.6 | 5.0 | 9.8 | 2.8 | 7.8 | 6.2 | 3.4 | 5.4 | 6.2 | 7.7 | Pr. | 13 centres in Europe and 1 in Saudi Arabia |
| FCGG registry | BelgiumRegional5.3 millionn | 2017–20192054 biopsies (A) | 61.1 (A)62/38 (A) | A | 17.3 | 9.3 | 4.7 | 5.5 | 0.7 | 4.2 | 7.2 | 3.4 | 7.5 | 10.7 | 6.2 | ERA-EDTA PRD | Flemish Collaborative Glomerulonephritis Group (FCGG) biopsy registry |
aNot mentioned; population of Italy in 1993.
bNot mentioned; population of Italy in 1998.
cNorth-Eastern region of Italy.
dPopulation of Lithuania in 2003.
e8/9 Scottish regions (82.4% of Scottish population).
fWestern Finland, one university hospital (UH, 0.4 million) + five central hospitals (CH, 0.8 million).
g38 years in 1976, 52 years in 2000.
h9% at CH, 14.7% at UH.
iNorth-Eastern and Western Romania.
jCovers ∼70% of all biopsies in Serbia.
kCovers ∼70% of all biopsies in Serbia.
lExact time frame not mentioned.
mInclusion of paediatric biopsies not explicitly mentioned in study.
nAdult population.
A: adult; AAV: ANCA-associated vasculitis and pauci-immune glomerulonephritis; AMY: amyloidosis; DKD: diabetic kidney disease; Dx: column showing the coding practice/list used in the study or registry; Freq.: column showing age category in which disease frequency was calculated (adult and/or paediatric biopsies); FSGS: focal segmental glomerulosclerosis; GN: glomerulonephritis; IgAN: IgA nephropathy; LN: lupus nephritis; MCD: minimal change disease; M/F: male/female distribution; MN: membranous nephropathy; MPGN: membranoproliferative glomerulonephritis; NA: not mentioned or not applicable; NScl: nephrosclerosis; P: paediatric; Pr.: proprietary coding list; TIN: tubulointerstitial nephritis.